Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more
Market Cap & Net Worth: Orchid Pharma Limited (ORCHPHARMA)
Orchid Pharma Limited (NSE:ORCHPHARMA) has a market capitalization of $316.75 Million (₹27.43 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #18435 globally and #880 in its home market, demonstrating a -4.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orchid Pharma Limited's stock price ₹540.85 by its total outstanding shares 50719105 (50.72 Million).
Orchid Pharma Limited Market Cap History: 2015 to 2026
Orchid Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $38.21 Million to $316.75 Million (23.21% CAGR).
Orchid Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orchid Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Orchid Pharma Limited's market cap is 0.05 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.45x
Orchid Pharma Limited's market cap is 0.45 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $15.84 Million | $8.59 Billion | -$2.79 Billion | 0.00x | N/A |
| 2017 | $10.95 Million | $7.97 Billion | -$4.95 Billion | 0.00x | N/A |
| 2018 | $2.81 Million | $6.83 Billion | -$3.53 Billion | 0.00x | N/A |
| 2019 | $3.19 Million | $6.00 Billion | $694.08 Million | 0.00x | 0.00x |
| 2020 | $72.18 Million | $4.84 Billion | -$1.31 Billion | 0.01x | N/A |
| 2021 | $231.27 Million | $4.50 Billion | -$1.17 Billion | 0.05x | N/A |
| 2022 | $213.20 Million | $5.60 Billion | -$19.51 Million | 0.04x | N/A |
| 2023 | $417.27 Million | $6.66 Billion | $463.18 Million | 0.06x | 0.90x |
| 2024 | $1.06 Billion | $8.19 Billion | $921.66 Million | 0.13x | 1.15x |
| 2025 | $444.48 Million | $9.22 Billion | $996.57 Million | 0.05x | 0.45x |
Competitor Companies of ORCHPHARMA by Market Capitalization
Companies near Orchid Pharma Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Orchid Pharma Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Orchid Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Orchid Pharma Limited's market cap moved from $38.21 Million to $ 316.75 Million, with a yearly change of 23.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹316.75 Million | -28.74% |
| 2025 | ₹444.48 Million | -58.00% |
| 2024 | ₹1.06 Billion | +153.62% |
| 2023 | ₹417.27 Million | +95.71% |
| 2022 | ₹213.20 Million | -7.81% |
| 2021 | ₹231.27 Million | +220.41% |
| 2020 | ₹72.18 Million | +2161.47% |
| 2019 | ₹3.19 Million | +13.54% |
| 2018 | ₹2.81 Million | -74.33% |
| 2017 | ₹10.95 Million | -30.87% |
| 2016 | ₹15.84 Million | -58.54% |
| 2015 | ₹38.21 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Orchid Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $316.75 Million USD |
| MoneyControl | $316.75 Million USD |
| MarketWatch | $316.75 Million USD |
| marketcap.company | $316.75 Million USD |
| Reuters | $316.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.